Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 132 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2014', provides an overview of the Systemic Sclerosis (Scleroderma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Systemic Sclerosis (Scleroderma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Systemic Sclerosis (Scleroderma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Systemic Sclerosis (Scleroderma) Overview 9
Therapeutics Development 10
Pipeline Products for Systemic Sclerosis (Scleroderma) - Overview 10
Pipeline Products for Systemic Sclerosis (Scleroderma) - Comparative Analysis 11
Systemic Sclerosis (Scleroderma) - Therapeutics under Development by Companies 12
Systemic Sclerosis (Scleroderma) - Therapeutics under Investigation by Universities/Institutes 15
Systemic Sclerosis (Scleroderma) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Systemic Sclerosis (Scleroderma) - Products under Development by Companies 19
Systemic Sclerosis (Scleroderma) - Products under Investigation by Universities/Institutes 21
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 22
Active Biotech AB 22
Allergan, Inc. 23
Angion Biomedica Corp. 24
arGentis Pharmaceuticals, LLC 25
Auspex Pharmaceuticals, Inc. 26
Bayer AG 27
BioLineRx, Ltd. 28
Bristol-Myers Squibb Company 29
Celgene Corporation 30
Corbus pharmaceuticals, Inc. 31
Daval International Ltd. 32
Digna Biotech, S.L. 33
F. Hoffmann-La Roche Ltd. 34
Fibrocell Science, Inc. 35
GlaxoSmithKline plc 36
iBio, Inc. 37
MedImmune, LLC 38
NovaLead Pharma Pvt. Ltd. 39
Therametrics holding AG 40
vida therapeutics inc. 41
VivaCell Biotechnology Espana S.L. 42
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
abatacept (recombinant) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
acALY-18 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Aimspro - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ANG-3070 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ARG-201 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
belimumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BL-1110 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CC-220 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DasKloster-0501-01 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
disitertide - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
GMHDFCOL-7 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
IBIOCFB-03 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
JBT-101 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MEDI-551 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NLP-491 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Oligonucleotide for Scleroderma - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
onabotulinumtoxin A - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
P-17 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
paquinimod - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PAT-048 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
pomalidomide - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
riociguat - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SD-560 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule to Inhibit NFkB for Immunology - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Stem Cell Therapy for Crohns Disease and Systemic Sclerosis - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
tocilizumab - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
V-2248 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
VCE-0048 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Systemic Sclerosis (Scleroderma) - Recent Pipeline Updates 98
Systemic Sclerosis (Scleroderma) - Dormant Projects 123
Systemic Sclerosis (Scleroderma) - Discontinued Products 124
Systemic Sclerosis (Scleroderma) - Product Development Milestones 125
Featured News & Press Releases 125
Oct 22, 2014: iBio Expands Exclusive Product Collaboration With Novici Biotech 125
Oct 01, 2014: Corbus Pharmaceuticals to Present at the 13th Annual BIO Investor Forum in San Francisco on Wednesday, October 8, 2014 125
Sep 30, 2014: Corbus Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014 126
Feb 25, 2014: Daval International Announces the Granting of Orphan Drug Designation by the FDA for AIMSPRO 126
Oct 07, 2013: "Treatment of Diffuse Systemic Sclerosis with AIMSPRO" Publication Features in October Edition of Annals of the Rheumatic Diseases Journal 126
Nov 30, 2012: Daval Announces Presentation Of Poster & Abstract On Phase II Study Of Hyperimmune Caprine Serum At ACR/ARHP 2012 Annual Meeting 127
Jul 30, 2012: Daval Announces Presentation Of Abstract On Results Of Encouraging Clinical Trends In Phase II Study Of Aimspro In Systemic Sclerosis At EULAR 2012 128
Oct 10, 2011: Daval Announces Positive Phase II Results For AIMSPRO As Monotherapy In Diffuse Scleroderma 128
Feb 20, 2011: Daval International Announces Completion Of Phase II Trial Evaluating Safety And Efficacy Of AIMSPRO 129
Nov 18, 2010: COMP Recommends Orphan Drug Status To Active Biotech's 57-57 Project 130
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 132
Disclaimer 132

List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2014 10
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Systemic Sclerosis (Scleroderma) - Pipeline by Active Biotech AB, H2 2014 22
Systemic Sclerosis (Scleroderma) - Pipeline by Allergan, Inc., H2 2014 23
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp., H2 2014 24
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals, LLC, H2 2014 25
Systemic Sclerosis (Scleroderma) - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 26
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2014 27
Systemic Sclerosis (Scleroderma) - Pipeline by BioLineRx, Ltd., H2 2014 28
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2014 29
Systemic Sclerosis (Scleroderma) - Pipeline by Celgene Corporation, H2 2014 30
Systemic Sclerosis (Scleroderma) - Pipeline by Corbus pharmaceuticals, Inc., H2 2014 31
Systemic Sclerosis (Scleroderma) - Pipeline by Daval International Ltd., H2 2014 32
Systemic Sclerosis (Scleroderma) - Pipeline by Digna Biotech, S.L., H2 2014 33
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 34
Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science, Inc., H2 2014 35
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline plc, H2 2014 36
Systemic Sclerosis (Scleroderma) - Pipeline by iBio, Inc., H2 2014 37
Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune, LLC, H2 2014 38
Systemic Sclerosis (Scleroderma) - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2014 39
Systemic Sclerosis (Scleroderma) - Pipeline by Therametrics holding AG, H2 2014 40
Systemic Sclerosis (Scleroderma) - Pipeline by vida therapeutics inc., H2 2014 41
Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana S.L., H2 2014 42
Assessment by Monotherapy Products, H2 2014 43
Number of Products by Stage and Target, H2 2014 45
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Systemic Sclerosis (Scleroderma) Therapeutics - Recent Pipeline Updates, H2 2014 98
Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2014 123
Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2014 124